Special Report: The Many Miracles of Biotech

Spinal cord injuries are some of the most devastating to the human body. The brain sends messages through your spinal cord to the other parts of your body. But with a damaged spinal cord, most parts of the body cannot function.

For those diagnosed as quadriplegics, there is almost no help available. A quadriplegic is someone whose four limbs are fully or semi-paralyzed, usually by a spinal cord injury.

For the most part, there was no hope for those with these devastating injuries…

Until now.

Scientists have successfully used stem cells to help six quadriplegics regain upper body functions. The lab that originally reported the results says that six months after the treatments, the six quadriplegics it treated have continued to show improvement.

This advancement is almost beyond belief — miraculous, many might say.

And it’s possible because of one specific field: biotech.

And that field is exploding.

How do I know this?

You’ve heard of the Nasdaq, right?

The Nasdaq was created in 1971 and was the first-ever electronic stock market. It’s the second-largest exchange in the world only behind the NYSE.

Why, you ask, are these exchanges important?

Well, that’s how we buy and sell stocks.

NasdaqHQ

Exchanges like the NYSE and the Nasdaq are an integral part of the market. Their ups and downs show us where the markets are headed and give analysts key indicators of when to buy and sell.

They’re a big deal.

This is why the Nasdaq Biotechnology Index (NBI) is so important.

The index is made up of biotechnology and pharmaceutical companies. And while it’s actually been around for the past 24 years, the past three years have shown something important...

The index jumped up more than 1900% from its open in 1993 to when it hit highs of $4,003.21 in July 2015.

This jump is important for one simple reason.

It means biotech is here to stay.

Biotech is responsible for huge advancements in medicine and science, like scientists using stem cells to try to bring brain-dead people back to life or using the study of genetics to try to cure diseases passed down in DNA like cystic fibrosis and sickle cell anemia.

Scientists in biotech are trying to make our world better by developing advancements in agriculture, medicine, and technology. Biotech could be responsible for curing cancer, diabetes, and eradicating worldwide hunger one day.

Biotech scientists studying genetics found a way to “clip” away “bad” genes and replace them with the correct genetic sequence. The advancement was called CRISPR-Cas9, and it was important because it allowed us to create a fast and cheap way to insert or remove genetic material with precision.

It looks like this:

Crispr

Just a few years ago, editing genetic code was an idea from science fiction.

Now, because of biotech, it’s our reality.

Biotech is a hugely profitable field with Grand View Research reporting that it estimates the global market for biotech to reach over $600 billion dollars by 2020…

That’s a whole lot of money.

That’s why the NBI exists.

And that’s why you need to invest in biotech today.

Exelixis, Inc. (NASDAQ: EXEL)

exel

Exelixis is a biopharmaceutical company that focuses on treatments and care for cancer patients. It recently worked out a deal with Takeda Pharmaceuticals to come out with a drug to treat liver cancer, which should be coming out of trials soon. Exelixis is working on getting out of debt and just paid back an $80.1 million dollar loan with a focus on reducing other debt. Its fourth-quarter report showed revenue up $77.6 million, up a huge amount from the previous year’s fourth-quarter revenue of $9.9 million. With a market cap of $6.2 billion and multiple products in testing, we see a strong 2017 ahead for Exelixis.

Illumina Inc. (NASDAQ GS: ILMN)

ilmn

Illumina is a big player in the field of genetics. It focuses on genetic analysis and created a machine that was able to sequence the human genome much faster and at a much better price than other companies. It has a market cap of $24.21 billion, and its fourth-quarter report for 2016 shows revenue up 5% from its third quarter, with revenue for the year up 8% and an operating cash flow of $280 million. This could be Illumina’s year as its semiconductor sequencing system is expected to go live in late 2017, bringing in large amounts of revenue.

Agilent Technologies, Inc. (NYSE: A)

Agilent

Agilent has a wide focus on life sciences, diagnostics, and applied chemicals. It works on genotyping and DNA mutation detection and on more personalized medicine where tech and medicine are personalized on a patient-by-patient basis. The company made headlines last year with its companion diagnostic array that found that a certain type of lung cancer responds to a specific drug — which had not been used before. The company has a market cap of $16.71 billion, and its fourth-quarter reports show that its revenue is up 7.3% with its Diagnostics and Genomics group up 8% and a fourth-quarter revenue of $193 million.


Energy and Capital, Copyright © 2017, Angel Publishing LLC. All rights reserved. 111 Market Place #720 Baltimore, MD 21202. The content of this site may not be redistributed without the express written consent of Angel Publishing. Individual editorials, articles and essays appearing on this site may be republished, but only with full attribution of both the author and Energy and Capital as well as a link to www.energyandcapital.com. Your privacy is important to us -- we will never rent or sell your e-mail or personal information. Please read our Privacy Policy. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Energy and Capital does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. The publisher, editors and consultants of Angel Publishing may actively trade in the investments discussed in this publication. They may have substantial positions in the securities recommended and may increase or decrease such positions without notice. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question.